[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496585":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":11,"id":53,"slug":11,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Southern California","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Zolpidem","EXPERIMENTAL",null,[13],"Drug: Zolpidem Tartrate 10 mg",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Zolpidem Tartrate 10 mg","two days preoperatively and five days postoperatively",[9],{"type":21,"name":15,"description":23,"armGroupLabels":26,"otherNames":11},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Pui Yan, MS","CONTACT","323-442-6984","puiyan@med.usc.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Keck Medical Center of USC","RECRUITING","Los Angeles","California","90033","United States",{"type":42,"coordinates":43},"Point",[44,45],-118.24368,34.05223,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Raymond Hah","Assistant Professor of Clinical Orthopaedic Surgery","100496585",false,"NCT05746143","The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion","The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion: A Randomized Control Trial","Inclusion Criteria:\n\n* degenerative lumbar disease\n* age of 18-75\n* undergoing open primary one- to three-level lumbar fusion\n\nExclusion Criteria:\n\n* currently use a sleep aid nightly\n* diagnosed with insomnia or sleep apnea\n* history of delirium with opiates or zolpidem\n* allergic to opiates or zolpidem\n* had previous lumbar spine surgery\n* undergoing minimally invasive lumbar fusion,\n* undergoing lumbar fusion for fracture, infection, tumor, or an inflammatory spondyloarthropathy","ALL","18 Years","75 Years",{"count":63,"type":64},140,"ESTIMATED","INTERVENTIONAL",[67],"PHASE4","The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.",[70,71,72,73],"Spine Fusion","Lumbar Spine Degeneration","Pain, Postoperative","Lumbar Spine Spondylosis",[75,9,76],"Lumbar Spine Fusion","Postoperative Outcomes","2026-04-29",{"date":79,"type":80},"2026-05-01","ACTUAL",{"date":82,"type":80},"2022-02-01",{"date":84,"type":64},"2030-12-31",{"name":5,"class":6},1]